Respiratory

Introducing artificial intelligence (AI)–powered robots like AMECA into health care comes with potential benefits like improved clinical decision-making and faster diagnoses, but also presents challenges such as misinformation risks and data privacy concerns.

Researchers say machine learning advances make it possible to use more sophisticated body composition analyses to assess risk of mortality from idiopathic pulmonary fibrosis (IPF).

Luca Richeldi, MD, PhD, outlined crucial lessons from recent idiopathic pulmonary fibrosis (IPF) trial failures, advocating for adaptive trial designs, rigorous statistical methods, and a focus on patient-relevant outcomes to enhance future research.

Speakers at the European Respiratory Society Congress 2024 provided updates to the 2 trials focusing on depemokimab for severe asthma and dupilumab for pediatric asthma.

New findings highlight the potential role of artificial intelligence in supporting health care professionals, but thorough testing is needed before its integration into everyday clinical practice.

“It's not unusual for complex disorders to have combination therapies,” says Martin Kolb, MD, PhD, professor of medicine at McMaster University.

Martin Kolb, MD, PhD, highlights the importance of taking time to explain the complexities of idiopathic pulmonary fibrosis (IPF) to patients before starting long-term treatment.

Also known as coal workers’ pneumoconiosis, black lung disease (or miner’s lung) is typically the result of inhaling coal dust for many years that causes scarring in the lungs and makes breathing increasingly difficult. The prevalence of black lung has been on the rise in the US.

Early intervention for idiopathic pulmonary fibrosis (IPF) is crucial due to the high mortality rate, with emerging therapies like nerandomilast showing potential to reduce health care costs by preventing disease progression.

The identification of unique pulmonary fibrosis endotypes is an important step in the development of precision medicine approaches for the incurable condition.

Looking to the future of bronchiectasis treatment, Panagis Galiatsatos, MD, MHS, outlines challenges in the current therapeutic landscape and discusses ways to potentially improve care.

A pulmonary specialist shares his approach to treating patients with bronchiectasis, highlighting gaps in knowledge that impact management practices.

Martin Kolb, MD, PhD, discusses the challenges of treating idiopathic pulmonary fibrosis (IPF) and highlights the potential benefits of a new PDE4B inhibitor, nerandomilast.

Panagis Galiatsatos, MD, MHS, provides clinical insights on resources and factors that inform the treatment of patients with bronchiectasis.

An expert on bronchiectasis describes the extensive impact of exacerbations on patients’ lives and the health care system.

While both drugs slowed down lung function decline in idiopathic pulmonary fibrosis (IPF), they were also linked to more deaths and increased incidence of acute exacerbation of IPF in real-world settings.

Patients with fibrosing interstitial lung disease (ILD) who began supplemental oxygen therapy had triple the per patient per month ILD-related health care costs compared with those who did not.

Type 2 diabetes and prediabetes can both significantly impact pulmonary health, highlighting the need for early detection and intervention.

The annual number of publications on macrophages and pulmonary fibrosis jumped during 2017 and 2020, with signs pointing to more focus on research in these fields.

Research highlighted the pivotal role of P2RX7 in driving inflammatory and fibrotic processes in idiopathic pulmonary fibrosis (IPF).

Underserved communities, already facing higher asthma prevalence due to social determinants of health, are disproportionately affected by the impact climate change is having on asthma exacerbations. Potential solutions include education for patients and health care providers, climate litigation to establish environmental rights, and policy changes to curb climate change.

Asthma is worsening under the effects of climate change, such as air pollution and pollen production, especially for underserved populations.

However, registry data also showed no significant difference in transplant-free survival and time to pulmonary function decline between patients receiving antifibrotics vs placebo.

More than 100 therapies for idiopathic pulmonary fibrosis are being developed across the globe.

The ENV-101 phase 2a trial for idiopathic pulmonary fibrosis (IPF) focused on assessing safety, lung function, and fibrosis, with plans for further trials, combination therapies, and strategies to manage adverse effects.